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Abstract 1 
 2 
Fully-sedated patients, being treated in the ICU, experience substantial skeletal muscle loss. 3 
Consequently, survival rate is reduced and full recovery after awakening is compromised. 4 
Neuromuscular electrical stimulation (NMES) represents an effective method to stimulate 5 
muscle protein synthesis and alleviate muscle disuse atrophy in healthy subjects. We investigated 6 
the efficacy of twice-daily NMES to alleviate muscle loss in six fully-sedated ICU patients 7 
admitted for acute critical illness (n=3 males, n=3 females; age 63±6 y; APACHE II disease 8 
severity-score: 29±2). One leg was subjected to twice-daily NMES of the quadriceps muscle for 9 
a period of 7±1 d while the other leg acted as non-stimulated control (CON). Directly before the 10 
first and on the morning after the final NMES session, quadriceps muscle biopsies were collected 11 
from both legs to assess muscle fiber-type specific cross-sectional area (CSA). Furthermore, 12 
phosphorylation status of key proteins involved in the regulation of muscle protein synthesis was 13 
assessed, and mRNA expression of selected genes was measured. In the CON leg, type I and 14 
type II muscle fiber CSA decreased by 16±9 and 24±7%, respectively (P<0.05). No muscle 15 
atrophy was observed in the stimulated leg. NMES increased mTOR phosphorylation by 19% 16 
when compared to baseline (P<0.05), with no changes in the CON leg. Furthermore, mRNA 17 
expression of key genes involved in muscle protein breakdown either declined (FOXO1; P<0.05) 18 
or remained unchanged (MAFBx and MuRF1), with no differences between legs. In conclusion, 19 
NMES represents an effective and feasible interventional strategy to prevent skeletal muscle 20 
atrophy in critically ill, comatose patients. 21 
 22 
Abstract word count: 249 23 
24 
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Introduction 25 
Critically ill patients suffer from extensive muscle wasting, which occurs rapidly at the onset of 26 
an ICU stay [1-3]. Aside from an increased risk of mortality [4, 5], consequences to this muscle 27 
loss include muscle weakness, prolonged mechanical ventilation, fatigue, decreases in muscle 28 
strength, impaired glucose homeostasis and delayed recovery and rehabilitation [6-9]. Muscle 29 
atrophy in ICU patients exceeds that seen in normal hospitalized or bedridden persons [10, 11]. 30 
Moreover, ICU patients who are mechanically ventilated and deeply sedated are thought to be 31 
even more susceptible to muscle wasting and subsequent negative health consequences due to a 32 
complete lack of muscle contraction. Despite this, no data are currently available concerning 33 
muscle fiber atrophy in this specific ICU patient subpopulation. 34 
Early ambulation has been proven a successful rehabilitation strategy in non-sedated ICU 35 
patients in terms of improving functional outcomes and overall prognosis [12]. However, in 36 
fully-sedated patients, early ambulation is not feasible and, as such, alternative strategies should 37 
be defined to alleviate muscle wasting. Neuromuscular electrical stimulation (NMES) is an 38 
effective means to invoke involuntary muscle contractions. Previously, NMES has been shown 39 
to attenuate the loss of muscle mass and strength experienced by non-sedated ICU patients [13] 40 
and healthy individuals subjected to limb immobilization [14]. However, the potential for NMES 41 
to rescue muscle mass in fully-sedated, comatose ICU patients has not been investigated. In the 42 
present study, we investigated our hypothesis that daily NMES attenuates skeletal muscle fiber 43 
atrophy in fully-sedated, comatose ICU patients. Fully-sedated ICU patients, expected to be 44 
sedated for a minimum of three days, were included in the present study. NMES was performed 45 
twice-daily on the quadriceps of one leg, whereas the other leg served as a sham-treated control. 46 
Prior to and immediately after the intervention, plasma samples were taken to assess any 47 
systemic changes in amino acid availability during the experiment, and muscle biopsies were 48 
taken from both legs to assess muscle fiber atrophy and myocellular characteristics. Additionally, 49 
RT-PCR and Western blotting were performed on collected muscle tissue samples to assess the 50 
potential impact of NMES on basal mRNA and protein expression levels of key genes involved 51 
in the regulation of muscle mass maintenance. 52 
53 
 4 
 
Methods 54 
 55 
Patients 56 
All patients admitted to the Intensive Care Unit (ICU) of Jessa Hospital, Hasselt, Belgium 57 
between March 2012 and July 2013 were assessed for eligibility for the present study (see 58 
eFigure1). Patients admitted to the ICU were screened by the nursing staff, and were excluded if 59 
one or more of the following exclusion criteria were met: <18 or >80 y old, not expected to 60 
undergo complete sedation, suffering from spinal cord injury, recent arterial surgery on the legs, 61 
local wounds that prohibit the application of neuromuscular electrical stimulation (NMES), 62 
chronic use of corticosteroids, intake of certain antithrombotic drugs, or the presence of an 63 
implantable cardioverter-defibrillator (ICD) and/or pacemaker. Secondly, the expected sedation 64 
time was estimated by the responsible physician and patients were excluded if this was <3 days. 65 
All patients who were excluded based on an expected short sedation time were re-evaluated after 66 
24 h, and included if the revised expected sedation time was >3 d. Participants were accepted 67 
into the study after written informed consent was obtained from their legal representatives. The 68 
study was approved by the Medical Ethical Committee of the Jessa Hospital in accordance with 69 
the Declaration of Helsinki. 70 
 71 
Study design 72 
An overview of the experimental protocol is depicted in eFigure 2. Patients were included in the 73 
study directly after informed consent was obtained from their legal representatives, which was 74 
generally given within 2.5 d after admission to the ICU (depicted in column ‘Time to inclusion’ 75 
in Table 1). After this, patient’s legs were randomly assigned as either the control (CON) or 76 
stimulated (NMES) leg, counterbalanced for left and right legs. Randomization was performed 77 
by an independent investigator, and treatment allocation was performed by using sequentially 78 
labeled envelopes which were opened after inclusion of subjects. Baseline measurements were 79 
then taken, which consisted of assessment of leg circumference (measured at different locations 80 
on the upper leg), obtaining an arterial blood sample, and obtaining a muscle biopsy from both 81 
legs. After the pre-measurements, NMES was performed twice-daily on one leg (NMES) 82 
whereas the other leg served as a control (CON). Post-measurements were performed on the final 83 
day of sedation, with a minimum study duration of 3 days and a maximum of 10 days. The study 84 
duration for each patient is depicted in Table 1. Post-measurements were performed prior to 85 
subjects being awake. Standard medical care was not altered, and passive mobilization was 86 
performed on both legs according to standard care procedures. 87 
 88 
Data collection 89 
At baseline, data on demographic and clinical characteristics of the patients were obtained, 90 
including information necessary to determine the severity of illness. These data were scored 91 
according to the Acute Physiology and Chronic Health Evaluation II (APACHE II) system with 92 
higher values indicating more severe illness and more therapeutic interventions, respectively 93 
[15].  94 
Arterial blood samples were collected from the catheter already placed in the arteria radialis. 95 
Blood (10 mL) was collected into EDTA-containing tubes and immediately centrifuged at 96 
1,000g for 10 min at 4°C. Aliquots of plasma were directly snap-frozen in liquid nitrogen and 97 
stored at -80°C until further analysis. Processing and storage of the samples was done by 98 
UBiLim (Universitaire Biobank Limburg, Hasselt, Belgium). Plasma amino acid concentrations 99 
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were measured using ultra-performance liquid chromatography tandem mass spectrometry as 100 
described previously [16], and results are displayed in eTable2. 101 
In addition, during the pre- and post-measurements, a muscle biopsy sample was collected from 102 
each leg. After injection of local anesthesia, percutaneous needle biopsy samples were collected 103 
from m. vastus lateralis, approximately 15 cm above the patella using the Bergström technique 104 
[17].  105 
 106 
Neuromuscular electrical stimulation 107 
Neuromuscular electrical stimulation sessions were performed both in the morning (11:00 AM) 108 
and afternoon (4.30 PM). Four self-adhesive electrodes (2 mm thick, 50 x 50 mm) were placed 109 
on the distal part at the muscle belly of the m. rectus femoris and the m. vastus lateralis, and at 110 
the inguinal area of both muscles. The electrodes were connected to an Enraf-Nonius TensMed 111 
S84 stimulation device (Enraf-Nonius, Rotterdam, the Netherlands), discharging biphasic 112 
symmetric rectangular-wave pulses. The position of the electrodes was re-marked daily with a 113 
semi-permanent marker to maintain the same location of stimulation for each session. The 114 
NMES protocol was composed of a warm-up phase (5 min, 5 Hz, 250 µs), a stimulation period 115 
(30 min, 100 Hz, 400 µs, 5 s on (0.75 s rise, 3.5 s contraction, 0.75 s fall) and 10 s off), and a 116 
cooling-down phase (5 min, 5 Hz, 250 µs). The intensity of the stimulation was set to a level at 117 
which full contractions of m. quadriceps femoris were both visible and palpable. The intensity 118 
was raised approximately every 3 min when a full muscle contraction was no longer achieved 119 
with the current intensity. This protocol was based on our previous work showing increased rates 120 
of muscle protein synthesis after a single bout of NMES [18], and applied on the immobilized 121 
leg of healthy young adults [14]. During the NMES sessions, four electrodes and compatible 122 
cables were also applied to the control leg to standardize all procedures (representing a sham 123 
treatment). 124 
 125 
Dietary intake 126 
When patients were hemodynamically stable, enteral feeding was started according to routine 127 
guidelines of the ICU at Jessa Hospital as early as possible. Patients were fed Nutrison Multi 128 
Fibre (containing 420 kJ, 16 en% protein, 49 en% carbohydrates, and 35 en% fat per 100 mL). 129 
Generally, patients were fed maximally 80 mL per hour with short intervals during which 130 
nutritional supply was paused. Gastric emptying was determined by the nursing staff, and food 131 
administration was altered accordingly. Nutritional support was not modulated and was applied 132 
according to the standard medical care in this ICU. 133 
 134 
Muscle analyses 135 
Muscle samples were freed from any visible non-muscle tissue and separated into different 136 
sections; the first part (~30 mg) was imbedded in Tissue-Tek (Sakura Finetek, Zoeterwoude, the 137 
Netherlands), frozen on liquid nitrogen cooled isopentane and used to determine muscle fiber-138 
type specific cross-sectional area (CSA) and satellite cell content as done previously.[19] The 139 
second part (~15 mg) was snap frozen in liquid nitrogen and used for real time-PCR analysis to 140 
determine mRNA expression of selected genes as described before,[14, 20] and compared with 141 
mRNA expression of n=6 healthy, age- and gender-matched controls. The third part (~40 mg) 142 
was snap frozen in liquid nitrogen for Western Blot analysis to determine the total content and 143 
phosphorylation status of several key proteins of interest as described previously [18]. All 144 
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muscle analyses were performed by an investigator blinded to treatment. A detailed overview of 145 
the muscle analyses is presented in the supplemental information. 146 
 147 
Statistics 148 
Based on data from previous studies in healthy subjects in our laboratory [14, 21], we calculated 149 
that 8 patients would be required to detect a 8% difference in muscle fiber CSA between CON 150 
and NMES over 7 days (using an α level of 0.05 and a β level of 0.10). All data presented are 151 
expressed as means±SEM. Baseline differences between legs were compared with a paired 152 
samples t-test. Pre- and post-intervention data were analyzed using repeated measures analysis of 153 
variance (ANOVA) with time (pre vs post) and treatment (CON vs NMES) as factors. Fiber type 154 
(type I vs type II) was added as a third within-subjects factor when analyzing all muscle fiber 155 
characteristics. In case of significant interaction (time x treatment), paired-samples t-tests were 156 
performed to determine time effects within the CON and NMES leg separately. Alternatively, 157 
when a time x treatment effect was observed for muscle fiber characteristics, a 2-way ANOVA 158 
was performed for the CON and NMES leg separately, with time and treatment as factors. For 159 
the mRNA analyses, differences between patients and healthy controls were tested by means of 160 
an independent samples t-test between the mean value of the CON and NMES leg in patients and 161 
the values observed in healthy controls. Statistical analyses were performed using the SPSS 162 
version 20.0 software package (SPSS Inc., Chicago, IL, USA), with P<0.05 as the value for 163 
statistical significance. 164 
165 
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Results 166 
 167 
Patients 168 
Between March 2012 and July 2013, 9 patients were included in the present study. Two patients 169 
awoke after <3 study days and one patient died. Therefore, the presented results represent data 170 
collected from 6 patients. Clinical characteristics of the included patients are listed in Table 1. 171 
Energy intake per day averaged 5.31±0.56 MJ, with a mean protein intake of 0.56±0.06 g·kg 172 
body weight-1·day-1. 173 
 174 
Neuromuscular electrical stimulation 175 
Within 5 min of the start of the actual 30 min stimulation period, a full muscle contraction was 176 
achieved. The intensity of the NMES intervention for subjects averaged 29.9 mA during the first 177 
session and was progressively increased to 32.3 mA in the final session.  178 
 179 
Muscle fiber characteristics 180 
Figure 1 illustrates the delta change in muscle fiber cross-sectional area (CSA) in both the 181 
NMES and CON legs throughout the study. Table 2 details skeletal muscle fiber type specific 182 
characteristics at baseline and following 7±1 d of full sedation in both legs. In the CON leg, a 183 
significant decline of 16±9% and 24±7% was observed in type I and II muscle fiber CSA, 184 
respectively (time effect; P<0.05). In contrast, the NMES leg showed no atrophy in either type I 185 
or II muscle fibers (time x treatment interaction effect; P<0.05). Muscle fiber type distribution 186 
showed an overall significant time x treatment interaction effect (see Table 2; P<0.05), with a 187 
shift from type I towards type II fibers in the CON leg, and a shift towards more type I fibers in 188 
the NMES leg. At baseline, satellite cell content was greater in type I vs type II muscle fibers 189 
(expressed per muscle fiber, per millimeter squared, and as a percentage of total myonuclei). No 190 
differences in muscle fiber type specific myonuclear content, myonuclear domain size or satellite 191 
cell content were observed between legs or over time. 192 
 193 
mRNA expression 194 
Figure 2 displays the relative muscle mRNA expression of key genes involved in the regulation 195 
of muscle protein synthesis and breakdown in the CON and NMES leg before and after the 196 
intervention, as well as for a group of healthy, age- and gender-matched controls. At baseline, 197 
mRNA expression did not differ between NMES and CON legs. However, MAFBx, MuRF1, 198 
FOXO1, mTOR and P70S6K were all more highly expressed in the patients compared with 199 
healthy controls (P<0.01). There was a significant time effect (P<0.05) such that FOXO1 and 200 
P70S6K expression decreased during the period of sedation, with no differences between legs. 201 
Expression levels for all other genes did not reveal any interaction or time effects. The mRNA 202 
expression of additional genes involved in the regulation of myogenesis, oxidative metabolism, 203 
mechano-sensing and cellular amino acid transport are presented in eFigure 3 (supplemental 204 
material). 205 
 206 
Signaling proteins 207 
The skeletal muscle content and phosphorylation status of key proteins involved in the regulation 208 
of muscle protein synthesis are displayed in Figure 3. Neither total protein content, nor 209 
phosphorylation status of Akt was affected by time or the intervention (both P>0.05). Whereas 210 
muscle mTOR content was unaffected by time or treatment, a significant time x treatment 211 
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interaction effect (P<0.05) was found for the phosphorylation status of mTOR. mTOR 212 
phosphorylation increased by as much as 19±5% in the NMES leg (P<0.05), with no changes in 213 
the CON leg (P>0.05). Muscle P70S6K total protein content decreased following the 214 
intervention in both legs (time effect, P<0.05), without changes in phosphorylation status 215 
(P>0.05). 216 
217 
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Discussion 218 
In the present study, we demonstrate for the first time that fully-sedated patients experience 219 
substantial type I and type II muscle fiber atrophy during a ~7 d stay in the ICU. Daily 220 
application of neuromuscular electrical stimulation (NMES) effectively prevents skeletal muscle 221 
fiber atrophy, offering an effective and feasible interventional strategy to alleviate muscle 222 
wasting in comatose ICU patients. 223 
General admission to the ICU has been shown to cause substantial muscle wasting [22] with a 224 
decline in type I and type II muscle fiber cross-sectional area of 3% and 4% per day, respectively 225 
[2]. In keeping with this, we show a 2.8% and 4.4% decline in muscle fiber size in type I and II 226 
muscle fibers, respectively, in fully-sedated patients (i.e. no possibility of voluntary muscle 227 
contraction) during on average 7 days in the ICU (Figure 1). By way of comparison, muscle 228 
atrophy brought about by disuse only in healthy humans (i.e. limb immobilization) leads to a 229 
0.5% and 0.9% per day decline in type I and II muscle fiber cross-sectional area (CSA), 230 
respectively [21]. This implies that the mechanisms responsible for muscle wasting in the ICU 231 
are not simply attributed to disuse. One possible contributing factor could be inadequate 232 
nutritional status. Sufficient dietary protein is considered a key factor in the maintenance of 233 
muscle mass [23-25], and previous research has shown that sufficient protein intake is associated 234 
with reduced mortality rates in critically ill patients [26, 27]. In the current study, patients 235 
received 0.56±0.06 g protein·kg body weight-1·day-1, which is below the current guidelines of 236 
1.3-2.0 g protein·kg body weight-1·day-1 recommended during critical illness [28, 29], and has 237 
likely contributed to the extensive level of muscle wasting. In support, plasma amino acid 238 
concentrations in our patients declined throughout the sedated state (eTable 2). In agreement, 239 
previous work has reported declines in circulating amino acid concentrations during critical 240 
illness [30]. Such a decline in circulating amino acid concentrations likely reduces amino acid 241 
uptake in muscle [31] and, as such, could modulate the efficacy of NMES as a means to 242 
stimulate muscle protein synthesis rates. 243 
From a mechanistic viewpoint, disuse atrophy has been primarily attributed to declines in muscle 244 
protein synthesis rates [20, 32-34]. However, it has been suggested that in various conditions 245 
associated with rapid muscle wasting a multitude of other factors (e.g. increased inflammation, 246 
higher metabolic stress responses etc.) may stimulate muscle proteolysis, driving much of the 247 
muscle loss [35]. In line with this, we see evidence of the severely metabolically compromised 248 
condition of our patients as demonstrated by numerous clinical chemistry indictors obtained 249 
throughout the study (e.g. high white blood cell counts and C-reactive protein (CRP) 250 
concentrations; eTable 1). In keeping with this, molecular markers that have been used as a 251 
proxy for changes in muscle protein breakdown rate were elevated upon admission to the ICU, 252 
when compared with a group of healthy subjects (i.e. MAFBx, MuRF1 and FOXO1; Figure 2). 253 
The subsequent decline in the expression levels of these genes suggest a decline in muscle 254 
protein turnover during hospital stay but expression levels remained elevated when compared to 255 
healthy controls. This is not unexpected given the metabolic stress response upon ICU admission 256 
[36]. In contrast to previous work investigating the impact of NMES on an immobilized leg [14], 257 
we observed no significant differences in the expression levels of various genes between the 258 
stimulated and unstimulated leg in this comatose ICU setting. The absence of such differences 259 
may be attributed to various factors, but underline our understanding that changes in the 260 
expression and phosphorylation levels of various genes being used as a proxy for changes in 261 
muscle protein breakdown and synthesis do not necessarily represent changes in muscle protein 262 
breakdown and synthesis rates and do not necessarily translate to a net increase or decrease in 263 
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muscle mass [37]. Taken together, the present data highlight the need for immediate and 264 
effective intervention at the onset of ICU admission to stimulate muscle protein synthesis and 265 
inhibit proteolysis, thereby preventing or attenuating extensive muscle wasting. An interesting 266 
observation in the stimulated leg was that NMES reversed the decline in phosphorylation status 267 
of mTOR (Figure 3D), which seems to be in line with previous work showing that NMES 268 
increases muscle protein synthesis rates [18]. 269 
Daily application of NMES has been shown to prevent muscle atrophy in healthy subjects during 270 
a week of leg immobilization [14]. Moreover, clinical trials have demonstrated beneficial effects 271 
of NMES on muscle function in various bed-rested populations, including patients suffering 272 
from COPD [38, 39] and sepsis [40, 41]. The current study demonstrates, for the first time, that 273 
NMES is capable of preventing muscle wasting in fully-sedated patients during 7 days in the 274 
ICU (with a +7±12% change in mixed muscle fiber CSA in the stimulated leg compared with a -275 
21±8% decline in mixed muscle fiber CSA in the control leg; Figure 1). The prevention of 276 
muscle atrophy in these individuals can have profound clinical implications. For instance, 277 
maintaining muscle mass during critical illness has been shown to reduce mortality rates [4, 5]. 278 
Additionally, since muscle mass is vital for functional capacity [42], metabolic homeostasis [9], 279 
and immune function [43], maintaining muscle mass during an ICU stay is essential to allow 280 
proper recovery during rehabilitation. As such, preventing muscle wasting is imperative for 281 
promoting quality of life after hospital discharge and reducing the likelihood of re-282 
hospitalization. NMES in fully-sedated patients can be easily applied by nursing staff, is 283 
relatively cheap and does not seem to cause any adverse effects on vital parameters during or 284 
after the sessions [44]. Some difficulties applying NMES in ICU patients have been reported 285 
previously and are likely due to increased skin/soft tissue impedance and/or edema [13]. Despite 286 
experiencing similar problems in the present study, all NMES sessions could be successfully 287 
performed without any adverse effects. Taken together, our data demonstrate that NMES is 288 
practical and feasible as a countermeasure for muscle wasting in clinically compromised ICU 289 
patients. Future studies should address whether these findings would translate into longer-term 290 
benefits such as increased survival rates, reduced hospitalization length of stay and/or improved 291 
rehabilitation outcomes. 292 
 293 
Conclusion 294 
NMES represents an effective and feasible interventional strategy to prevent skeletal muscle 295 
wasting in critically ill, comatose patients. NMES may be applied effectively to offset negative 296 
consequences of muscle wasting and, as such, may increase survival and improve subsequent 297 
rehabilitation in these patients. 298 
 299 
Clinical Perspectives 300 
Fully-sedated patients experience substantial skeletal muscle loss that reduces survival rate and 301 
compromises full recovery. We investigated the efficacy of twice-daily neuromuscular electrical 302 
stimulation (NMES) to attenuate skeletal muscle loss in fully-sedated ICU patients admitted for 303 
acute critical illness. The non-stimulated leg showed substantial type I and type II muscle fiber 304 
atrophy (a 16±9 and 24±7% decline in muscle fiber cross sectional area, respectively; P<0.05). 305 
In contrast, no atrophy was observed in the muscle fibers collected from the stimulated leg. Both 306 
mRNA and protein expression of key proteins involved in muscle protein metabolism were 307 
assessed to understand the molecular mechanisms involved. In conclusion, NMES represents an 308 
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effective and feasible interventional strategy to prevent skeletal muscle atrophy in critically ill, 309 
comatose patients. 310 
 
  
 12 
 
Author contributions 
M.L. Dirks had full access to all of the data in the study and takes responsibility for the integrity 
of the data and the accuracy of the data. None of the authors disclose any conflicts of interest. 
Study concept and design: M.L. Dirks, D. Hansen, A.van Assche, P. Dendale, and L.J.C. van 
Loon. Acquisition of data: M.L. Dirks and D. Hansen. Analysis and interpretation of the data: 
M.L. Dirks, D. Hansen, P. Dendale and L.J.C. van Loon. Drafting of the manuscript: M.L. Dirks. 
Critical revision of the manuscript for important intellectual content: D. Hansen, A. van Assche, 
P. Dendale and L.J.C. van Loon.  Study supervision: A. van Assche, P. Dendale and L.J.C. van 
Loon. 
 
Additional contributions 
We gratefully acknowledge the enthusiasm and assistance of the physicians and nursing staff of 
the ICU in Jessa Hospital, with special thanks to Dr. P. Vranckx for his practical assistance. We 
would also like to thank Marika Leenders and Lex B. Verdijk for their practical support and 
Benjamin T. Wall for his assistance in drafting the manuscript. Furthermore, we are thankful for 
the assistance of dr. E. Bijnens, Department of Radiology at Jessa Hospital, and for the support 
and assistance provided by Biobank UbiLim at Jessa Hospital for processing and storage of the 
samples.
 13 
 
References 
 
1. Monk, D.N., Plank, L.D., Franch-Arcas, G., Finn, P.J., Streat, S.J., and Hill, G.L. (1996) 
Sequential changes in the metabolic response in critically injured patients during the first 
25 days after blunt trauma. Ann Surg 223, 395-405 
2. Helliwell, T.R., Wilkinson, A., Griffiths, R.D., McClelland, P., Palmer, T.E., and Bone, 
J.M. (1998) Muscle fibre atrophy in critically ill patients is associated with the loss of 
myosin filaments and the presence of lysosomal enzymes and ubiquitin. Neuropathol 
Appl Neurobiol 24, 507-17 
3. Latronico, N. and Bolton, C.F. (2011) Critical illness polyneuropathy and myopathy: a 
major cause of muscle weakness and paralysis. Lancet Neurol 10, 931-41 
4. Weijs, P.J., Looijaard, W.G., Dekker, I.M., Stapel, S.N., Girbes, A.R., Oudemans-van 
Straaten, H.M., and Beishuizen, A. (2014) Low skeletal muscle area is a risk factor for 
mortality in mechanically ventilated critically ill patients. Crit Care 18, R12 
5. Moisey, L.L., Mourtzakis, M., Cotton, B.A., Premji, T., Heyland, D.K., Wade, C.E., 
Bulger, E., Kozar, R.A., for the, N., and Rehabilitation Investigators, C. (2013) Skeletal 
muscle predicts ventilator-free days, ICU-free days, and mortality in elderly ICU patients. 
Crit Care 17, R206 
6. Levine, S., Nguyen, T., Taylor, N., Friscia, M.E., Budak, M.T., Rothenberg, P., Zhu, J., 
Sachdeva, R., Sonnad, S., Kaiser, L.R., Rubinstein, N.A., Powers, S.K., and Shrager, J.B. 
(2008) Rapid disuse atrophy of diaphragm fibers in mechanically ventilated humans. N 
Engl J Med 358, 1327-35 
7. Herridge, M.S. (2009) Legacy of intensive care unit-acquired weakness. Crit Care Med 
37, S457-61 
8. Truong, A.D., Fan, E., Brower, R.G., and Needham, D.M. (2009) Bench-to-bedside 
review: mobilizing patients in the intensive care unit--from pathophysiology to clinical 
trials. Crit Care 13, 216 
9. Nair, K.S. (2005) Aging muscle. Am J Clin Nutr 81, 953-63 
10. Puthucheary, Z.A., Rawal, J., McPhail, M., Connolly, B., Ratnayake, G., Chan, P., 
Hopkinson, N.S., Padhke, R., Dew, T., Sidhu, P.S., Velloso, C., Seymour, J., Agley, 
C.C., Selby, A., Limb, M., Edwards, L.M., Smith, K., Rowlerson, A., Rennie, M.J., 
Moxham, J., Harridge, S.D., Hart, N., and Montgomery, H.E. (2013) Acute skeletal 
muscle wasting in critical illness. JAMA 310, 1591-600 
11. Wall, B.T. and van Loon, L.J. (2013) Nutritional strategies to attenuate muscle disuse 
atrophy. Nutr Rev 71, 195-208 
12. Schweickert, W.D., Pohlman, M.C., Pohlman, A.S., Nigos, C., Pawlik, A.J., Esbrook, 
C.L., Spears, L., Miller, M., Franczyk, M., Deprizio, D., Schmidt, G.A., Bowman, A., 
Barr, R., McCallister, K.E., Hall, J.B., and Kress, J.P. (2009) Early physical and 
occupational therapy in mechanically ventilated, critically ill patients: a randomised 
controlled trial. Lancet 373, 1874-82 
13. Rodriguez, P.O., Setten, M., Maskin, L.P., Bonelli, I., Vidomlansky, S.R., Attie, S., 
Frosiani, S.L., Kozima, S., and Valentini, R. (2012) Muscle weakness in septic patients 
requiring mechanical ventilation: protective effect of transcutaneous neuromuscular 
electrical stimulation. J Crit Care 27, 319 e1-8 
 14 
 
14. Dirks, M.L., Wall, B.T., Snijders, T., Ottenbros, C.L., Verdijk, L.B., and van Loon, L.J. 
(2014) Neuromuscular electrical stimulation prevents muscle disuse atrophy during leg 
immobilization in humans. Acta Physiol (Oxf) 210, 628-41 
15. Knaus, W.A., Draper, E.A., Wagner, D.P., and Zimmerman, J.E. (1985) APACHE II: a 
severity of disease classification system. Crit Care Med 13, 818-29 
16. Waterval, W.A., Scheijen, J.L., Ortmans-Ploemen, M.M., Habets-van der Poel, C.D., and 
Bierau, J. (2009) Quantitative UPLC-MS/MS analysis of underivatised amino acids in 
body fluids is a reliable tool for the diagnosis and follow-up of patients with inborn errors 
of metabolism. Clin Chim Acta 407, 36-42 
17. Bergstrom, J. (1975) Percutaneous needle biopsy of skeletal muscle in physiological and 
clinical research. Scand J Clin Lab Invest 35, 609-16 
18. Wall, B.T., Dirks, M.L., Verdijk, L.B., Snijders, T., Hansen, D., Vranckx, P., Burd, N.A., 
Dendale, P., and van Loon, L.J. (2012) Neuromuscular electrical stimulation increases 
muscle protein synthesis in elderly type 2 diabetic men. Am J Physiol Endocrinol Metab 
303, E614-23 
19. Leenders, M., Verdijk, L.B., van der Hoeven, L., van Kranenburg, J., Nilwik, R., and van 
Loon, L.J. (2013) Elderly men and women benefit equally from prolonged resistance-
type exercise training. J Gerontol A Biol Sci Med Sci 68, 769-79 
20. Wall, B.T., Snijders, T., Senden, J.M., Ottenbros, C.L., Gijsen, A.P., Verdijk, L.B., and 
van Loon, L.J. (2013) Disuse impairs the muscle protein synthetic response to protein 
ingestion in healthy men. J Clin Endocrinol Metab 98, 4872-81 
21. Snijders, T., Wall, B.T., Dirks, M.L., Senden, J.M., Hartgens, F., Dolmans, J., Losen, M., 
Verdijk, L.B., and van Loon, L.J. (2014) Muscle disuse atrophy is not accompanied by 
changes in skeletal muscle satellite cell content. Clin Sci (Lond) 126, 557-66 
22. Reid, C.L., Campbell, I.T., and Little, R.A. (2004) Muscle wasting and energy balance in 
critical illness. Clin Nutr 23, 273-80 
23. Paddon-Jones, D., Sheffield-Moore, M., Zhang, X.J., Volpi, E., Wolf, S.E., Aarsland, A., 
Ferrando, A.A., and Wolfe, R.R. (2004) Amino acid ingestion improves muscle protein 
synthesis in the young and elderly. Am J Physiol Endocrinol Metab 286, E321-8 
24. Rennie, M.J., Edwards, R.H., Halliday, D., Matthews, D.E., Wolman, S.L., and Millward, 
D.J. (1982) Muscle protein synthesis measured by stable isotope techniques in man: the 
effects of feeding and fasting. Clin Sci 63, 519-23 
25. Volpi, E., Mittendorfer, B., Wolf, S.E., and Wolfe, R.R. (1999) Oral amino acids 
stimulate muscle protein anabolism in the elderly despite higher first-pass splanchnic 
extraction. The American journal of physiology 277, E513-20 
26. Strack van Schijndel, R.J., Weijs, P.J., Koopmans, R.H., Sauerwein, H.P., Beishuizen, A., 
and Girbes, A.R. (2009) Optimal nutrition during the period of mechanical ventilation 
decreases mortality in critically ill, long-term acute female patients: a prospective 
observational cohort study. Crit Care 13, R132 
27. Weijs, P.J., Stapel, S.N., de Groot, S.D., Driessen, R.H., de Jong, E., Girbes, A.R., Strack 
van Schijndel, R.J., and Beishuizen, A. (2012) Optimal protein and energy nutrition 
decreases mortality in mechanically ventilated, critically ill patients: a prospective 
observational cohort study. JPEN J Parenter Enteral Nutr 36, 60-8 
28. Martindale, R.G., McClave, S.A., Vanek, V.W., McCarthy, M., Roberts, P., Taylor, B., 
Ochoa, J.B., Napolitano, L., Cresci, G., American College of Critical Care, M., and 
Directors, A.S.P.E.N.B.o. (2009) Guidelines for the provision and assessment of nutrition 
 15 
 
support therapy in the adult critically ill patient: Society of Critical Care Medicine and 
American Society for Parenteral and Enteral Nutrition: Executive Summary. Crit Care 
Med 37, 1757-61 
29. Singer, P., Berger, M.M., Van den Berghe, G., Biolo, G., Calder, P., Forbes, A., Griffiths, 
R., Kreyman, G., Leverve, X., Pichard, C., and Espen (2009) ESPEN Guidelines on 
Parenteral Nutrition: intensive care. Clin Nutr 28, 387-400 
30. Jespersen, J.G., Nedergaard, A., Reitelseder, S., Mikkelsen, U.R., Dideriksen, K.J., 
Agergaard, J., Kreiner, F., Pott, F.C., Schjerling, P., and Kjaer, M. (2011) Activated 
protein synthesis and suppressed protein breakdown signaling in skeletal muscle of 
critically ill patients. PLoS One 6, e18090 
31. Pennings, B., Groen, B., de Lange, A., Gijsen, A.P., Zorenc, A.H., Senden, J.M., and van 
Loon, L.J. (2012) Amino acid absorption and subsequent muscle protein accretion 
following graded intakes of whey protein in elderly men. Am J Physiol Endocrinol Metab 
302, E992-9 
32. Biolo, G., Ciocchi, B., Lebenstedt, M., Barazzoni, R., Zanetti, M., Platen, P., Heer, M., 
and Guarnieri, G. (2004) Short-term bed rest impairs amino acid-induced protein 
anabolism in humans. J Physiol 558, 381-8 
33. Biolo, G., Ciocchi, B., Lebenstedt, M., Heer, M., and Guarnieri, G. (2002) Sensitivity of 
whole body protein synthesis to amino acid administration during short-term bed rest. J 
Gravit Physiol 9, P197-8 
34. Glover, E.I., Phillips, S.M., Oates, B.R., Tang, J.E., Tarnopolsky, M.A., Selby, A., Smith, 
K., and Rennie, M.J. (2008) Immobilization induces anabolic resistance in human 
myofibrillar protein synthesis with low and high dose amino acid infusion. The Journal of 
physiology 586, 6049-61 
35. Egerman, M.A. and Glass, D.J. (2014) Signaling pathways controlling skeletal muscle 
mass. Crit Rev Biochem Mol Biol 49, 59-68 
36. Constantin, D., McCullough, J., Mahajan, R.P., and Greenhaff, P.L. (2011) Novel events 
in the molecular regulation of muscle mass in critically ill patients. J Physiol 589, 3883-
95 
37. Greenhaff, P.L., Karagounis, L.G., Peirce, N., Simpson, E.J., Hazell, M., Layfield, R., 
Wackerhage, H., Smith, K., Atherton, P., Selby, A., and Rennie, M.J. (2008) 
Disassociation between the effects of amino acids and insulin on signaling, ubiquitin 
ligases, and protein turnover in human muscle. Am J Physiol Endocrinol Metab 295, 
E595-604 
38. Abdellaoui, A., Prefaut, C., Gouzi, F., Couillard, A., Coisy-Quivy, M., Hugon, G., 
Molinari, N., Lafontaine, T., Jonquet, O., Laoudj-Chenivesse, D., and Hayot, M. (2011) 
Skeletal muscle effects of electrostimulation after COPD exacerbation: a pilot study. Eur 
Respir J 38, 781-8 
39. Zanotti, E., Felicetti, G., Maini, M., and Fracchia, C. (2003) Peripheral muscle strength 
training in bed-bound patients with COPD receiving mechanical ventilation: effect of 
electrical stimulation. Chest 124, 292-6 
40. Poulsen, J.B., Moller, K., Jensen, C.V., Weisdorf, S., Kehlet, H., and Perner, A. (2011) 
Effect of transcutaneous electrical muscle stimulation on muscle volume in patients with 
septic shock. Crit Care Med 39, 456-61 
41. Rodriguez, P.O., Setten, M., Maskin, L.P., Bonelli, I., Vidomlansky, S.R., Attie, S., 
Frosiani, S.L., Kozima, S., and Valentini, R. (2011) Muscle weakness in septic patients 
 16 
 
requiring mechanical ventilation: Protective effect of transcutaneous neuromuscular 
electrical stimulation. Journal of critical care  
42. Maughan, R.J., Watson, J.S., and Weir, J. (1983) Strength and cross-sectional area of 
human skeletal muscle. J Physiol 338, 37-49 
43. Nielsen, S. and Pedersen, B.K. (2008) Skeletal muscle as an immunogenic organ. Curr 
Opin Pharmacol 8, 346-51 
44. Meesen, R.L.J., Dendale, P., Cuypers, K., Berger, J., Hermans, A., Thijs, H., and Levin, 
O. (2010) Neuromuscular Electrical Stimulation as a Possible Means to Prevent Muscle 
Tissue Wasting in Artificially Ventilated and Sedated Patients in the Intensive Care Unit: 
A Pilot Study. Neuromodulation 13, 315-321 
 
 17 
 
Figure legends 
 
Figure 1: Changes in muscle fiber cross sectional area (CSA) in the control (CON) and 
stimulated (NMES) leg of sedated patients, after 7±1 days of twice-daily NMES. A significant 
interaction effect (P<0.05) was observed, and a time effect in the CON leg (P<0.05). * 
Significantly change different from zero (P<0.05). 
 
Figure 2: Skeletal muscle mRNA expression of genes of interest. Abbreviations: FOXO1, 
Forkhead box protein O1; MAFbx, Muscle Atrophy F-box; MuRF1, Muscle RING-finger 
protein-1; mTOR, mammalian target of rapamycin; P70S6K, P70S6 kinase. * Significantly 
different from patients at baseline (P<0.05). # Significantly different from pre-value (P<0.05). 
 
Figure 3: Skeletal muscle protein expression of Akt, mTOR and P70S6K in the control (CON) 
and stimulated (NMES) leg, before (white bars) and after (black bars) 7±1 days of twice-daily 
NMES. Left graphs: total protein expression, right graphs: phosphorylated/total expression. 
Abbreviations: mTOR, mammalian target of rapamycin; P70S6K, P70S6 kinase. * Significantly 
different from pre-intervention values (P<0.05). 
 
